List view / Grid view
13 May 2015 | By Victoria White
Under the terms of an existing agreement with Selecta, Sanofi has exercised its option to an exclusive license to develop a treatment of coeliac disease...
13 May 2015 | By Victoria White
Genethon and Selecta Biosciences have announced an ongoing research collaboration with the goal of enabling repeat dosing for gene therapies...
13 May 2015 | By Victoria White
Soligenix has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for RiVax...
13 May 2015 | By Victoria White
A Phase I clinical trial of INVAC-1, an innovative therapeutic DNA vaccine, which specifically targets the telomerase enzyme (hTERT), has commenced...
12 May 2015 | By
Scientists from TSRI and NIH have mapped out the structure of an important protein involved in cellular function and nervous system development - TTLL7...
12 May 2015 | By Victoria White
Mainz-based researchers have made significant advances with regard to the development of individualised cancer immunotherapy strategies...
12 May 2015 | By Victoria White
Cyclenium Pharma and Haplogen have signed a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas...
12 May 2015 | By Victoria White
BioNTech and Lilly are to collaborate to identify and validate novel tumour targets and their corresponding TCRs in one or more types of cancer...
11 May 2015 | By Victoria White
Cidara Therapeutics has announced that the FDA has designated the Company’s lead antifungal product candidate, CD101 IV, as a QIDP with Fast Track status...
11 May 2015 | By Victoria White
Novogen, in conjunction with Australian paediatric cancer researchers, released key preclinical data on experimental cancer drug-candidate, TRXE-009...
11 May 2015 | By Victoria White
UNC-Chapel Hill and GSK have announced the creation of a dedicated HIV Cure centre and a new company that will focus on discovering a cure for HIV/AIDS...
11 May 2015 | By Victoria White
Hemispherx Biopharma has received formal notification approving its Orphan Medicinal Product Application for Ampligen for the treatment of Ebola...
11 May 2015 | By Victoria White
PhoreMost has been selected to receive a funding award of £1.4M from Innovate UK to develop its lead oncology programme targeting mutant KRAS cancers...
11 May 2015 | By Victoria White
Isarna Therapeutics presented preclinical data for its lead candidate ISTH0036 in one podium presentation and two poster publications at ARVO 2015...
11 May 2015 | By Victoria White
US and EU Patent Offices have granted Domainex patents for the first generation of inhibitor compounds in its lead programme targeting IKK epsilon and TBK1.
